

Review of: "[Research Note] Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent"

RAVICHANDIRAN Ravichandiran

Potential competing interests: No potential competing interests to declare.

Revision comments

1. "Semaglutide, a GLP1 agonist similar to Ozempic." This sentence needs to be changed. Semaglutide is an ingredient of the brand name "Ozempic."
2. Page 3/5: It should be "exenatide" in place of "eventide."
3. A well-defined hypothesis is proposed. However, all those data need to be supported by evidence from preclinical and clinical data for anticancer effect (*in vitro* and *in vivo*); semaglutide's anticancer efficacy with *invivo* and *invitro* results is lacking in relation to its anticancer potential.
4. Only positive aspects have been discussed. However, a few negative reports are available. They should also be brought here. Overall, all the reports from clinical studies should be included.
5. The dose, modes of administration, duration, and side effects of semaglutide have to be included.
6. Furthermore, clinical research demonstrating semaglutide's anticancer value should be mentioned and provided for clarity.
7. Details on the selectivity and particular use of semaglutide over other GLP1 agonists have been omitted.
8. There is no clarification as to why exenatide was referenced while the whole paper is focused on semaglutide.
9. Make certain portions of the draft more language simple for improved reading. Some phrases are difficult to read and comprehend.
11. The whole work lacks graphical representation for MAPK, NFkB, PI3K, and other interlink pathways.